These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19761157)

  • 1. Further progress in the treatment of multiple myeloma?
    Malik PS; Kumar L
    Natl Med J India; 2009; 22(1):25-7. PubMed ID: 19761157
    [No Abstract]   [Full Text] [Related]  

  • 2. New evidence in oncologic and cardiocirculatory medicine.
    Conti AA; Dilaghi B; Modesti PA; Nozzoli C
    Intern Emerg Med; 2009 Feb; 4(1):57-9. PubMed ID: 19082927
    [No Abstract]   [Full Text] [Related]  

  • 3. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current perspectives in the treatment of multiple myeloma - news and views].
    Knop S
    Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

  • 12. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial mass of multiple myeloma with good response to chemotherapy.
    Synhaeve NE; van der Heul C; Tijssen CC
    BMJ Case Rep; 2012 Sep; 2012():. PubMed ID: 23035155
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 15. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
    Chen Z; Wang W; Rich A; Tang G; Hu S
    Am J Hematol; 2015 Aug; 90(8):E146-8. PubMed ID: 25960187
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multiple myeloma and other plasma cell dyscrasias].
    del Potro Gómez E; Morales Sanz D
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():52-7. PubMed ID: 10422451
    [No Abstract]   [Full Text] [Related]  

  • 17. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 19. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 20. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.